Yoram Bouhnik

Yoram Bouhnik

Neuilly-sur-seine, 92600, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 162 publications

Crohn's Disease Activity Index in the era of obesity: time to abandon it?

Crohn's Disease Activity Index in the era of obesity: time to abandon it?

Journal: Journal of Crohn's & colitis

Published: May 12, 2026

Screening for osteoporosis in patients with inflammatory bowel diseases: a cross-sectional study.

Screening for osteoporosis in patients with inflammatory bowel diseases: a cross-sectional study.

Journal: Clinical rheumatology

Published: December 19, 2025

Five-year effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.

Five-year effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.

Journal: Clinics and research in hepatology and gastroenterology

Published: October 04, 2025

A randomized controlled trial of antibiotics targeting adherent and invasive Escherichia coli versus placebo in Crohn's disease: the TEOREM trial.

A randomized controlled trial of antibiotics targeting adherent and invasive Escherichia coli versus placebo in Crohn's disease: the TEOREM trial.

Journal: Journal of Crohn's & colitis

Published: June 13, 2025

A new endoscopic paradigm: evaluating the EASE-CD score for Crohn's disease.

A new endoscopic paradigm: evaluating the EASE-CD score for Crohn's disease.

Journal: The lancet. Gastroenterology & hepatology

Published: April 08, 2025

Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.

Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.

Journal: Drugs - real world outcomes

Published: January 17, 2025

Impact of Histological Remission for Predicting Clinical Relapse in Crohn's Disease: A Post Hoc Analysis of the Prospective STORI Cohort.

Impact of Histological Remission for Predicting Clinical Relapse in Crohn's Disease: A Post Hoc Analysis of the Prospective STORI Cohort.

Journal: Journal of Crohn's & colitis

Published: November 02, 2024

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.

Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.

Journal: Drugs - real world outcomes

Published: September 26, 2024

Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.

Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: September 03, 2024

The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease.

The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease.

Journal: Journal of Crohn's & colitis

Published: August 29, 2024

Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study).

Real-world effectiveness and safety of CT-P13, an infliximab biosimilar, for inflammatory bowel diseases: A prospective national observational cohort study (ReFLECT study).

Journal: Clinics and research in hepatology and gastroenterology

Published: July 19, 2024

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.

Journal: The lancet. Gastroenterology & hepatology

Published: July 17, 2024

Showing 1-12 of 162

Last Updated: 09/26/2026